Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 658 matching trials from the live ClinicalTrials.gov search.
Conditions
Asthma, COPD
Interventions
n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Post-operative Urinary Retention
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
Anand Rughani, MD
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Maine
Conditions
Myelodysplastic Syndrome
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Kristin R Hoffman
Other
Eligibility
Up to 6 Hours
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Sacramento, California
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Acute Effects on Stem Cell Surveillance

NCT07341178
Conditions
Stem Cell Surveillance
Interventions
Anthocyanin-rich berry extract, Anthocyanin-rich flower/leaf extract, Berry /leaf blend, Placebo
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Klamath Falls, Oregon
Conditions
Breast Cancer, Social Determinants of Health (SDOH)
Interventions
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vortioxetine, Duloxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
66
States / cities
Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Conditions
Traumatic Brain Injury
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Conditions
Dry Needling
Interventions
Delphi Questionaire
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Youngstown, Ohio
Conditions
Non-small-cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Rockville, Maryland • Boston, Massachusetts + 1 more
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185
Conditions
Solid Tumor, Adult
Interventions
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
Drug
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more
Conditions
Healthy Adults
Interventions
Crucera-SGS, Meriva 500-SF
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Interventions
Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Tucson, Arizona • Daly City, California • San Diego, California + 33 more
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Conditions
Ovarian Neoplasms
Interventions
Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Innovative Intervention for OUD Treatment

NCT04325659
Conditions
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Interventions
Bridge Device, Lofexidine, Placebo, Sham Bridge Device
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pleuropulmonary Blastoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
80
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
Conditions
Advanced Solid Tumors
Interventions
ginisortamab, trifluridine/tipiracil, mFOLFOX6
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Charleston, South Carolina • Houston, Texas
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans II

NCT07043452
Conditions
Healthy Volunteers
Interventions
Blinded Study Medication - Condition 1, Blinded Study Medication - Condition 2, Blinded Study Medication - Condition 3, Blinded Study Medication - Condition 4, Blinded Study Medication - Condition 5, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia